

Shi-Ming Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1210157/publications.pdf>

Version: 2024-02-01

60
papers

2,866
citations

331538

21
h-index

168321

53
g-index

60
all docs

60
docs citations

60
times ranked

2924
citing authors

#	ARTICLE	IF	CITATIONS
1	Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 213-219.	0.8	10
2	GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial. <i>Hepatology International</i> , 2022, 16, 148.	1.9	6
3	Contemporary real-world evidence in unresectable HCC (uHCC) patients treated with regorafenib in Taiwan: Interim results from the observational REFINE study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 402-402.	0.8	0
4	Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization. <i>Diagnostics</i> , 2022, 12, 665.	1.3	4
5	Proton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. <i>Cancers</i> , 2022, 14, 1616.	1.7	1
6	Soluble form of CTLA4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients. <i>Cancer Medicine</i> , 2022, 11, 3786-3795.	1.3	5
7	Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.. <i>American Journal of Cancer Research</i> , 2022, 12, 1899-1911.	1.4	0
8	Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.. <i>American Journal of Cancer Research</i> , 2022, 12, 1606-1620.	1.4	0
9	Real-time virtual sonography-assisted radiofrequency ablation in liver tumors with conspicuous or inconspicuous images or peritumoral landmarks under ultrasonography. <i>Abdominal Radiology</i> , 2021, 46, 2814-2822.	1.0	2
10	A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness. <i>PLoS ONE</i> , 2021, 16, e0249003.	1.1	2
11	Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma. <i>European Radiology</i> , 2021, 31, 8649-8661.	2.3	2
12	Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 2319-2330.	1.4	3
13	MELD score is the better predictor for 30-day mortality in patients with ruptured hepatocellular carcinoma treated by trans-arterial embolization. <i>American Journal of Cancer Research</i> , 2021, 11, 3726-3734.	1.4	1
14	Complete response at first transarterial chemoembolization predicts favorable outcome in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 4956-4965.	1.4	2
15	The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 635-643.	0.8	7
16	Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1192-1199.	0.8	9
17	Functional Genomics Identifies Hepatitis-Induced STAT3-TYRO3-STAT3 Signaling as a Potential Therapeutic Target of Hepatoma. <i>Clinical Cancer Research</i> , 2020, 26, 1185-1197.	3.2	12
18	Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 23.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2020, 59, 1269-1279.	1.3	10
20	Prolonged post-ablation fever may predict one-year tumor recurrence in hepatocellular carcinoma after radiofrequency ablation. <i>International Journal of Hyperthermia</i> , 2020, 37, 1008-1015.	1.1	3
21	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. <i>Liver Cancer</i> , 2020, 9, 245-260.	4.2	172
22	Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. <i>Advances in Digestive Medicine</i> , 2020, 7, 83-92.	0.1	2
23	Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1239-1246.	0.8	4
24	Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. <i>Abdominal Radiology</i> , 2019, 44, 1141-1151.	1.0	19
25	Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase. <i>Hepatology</i> , 2019, 69, 1412-1425.	3.6	26
26	Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions. <i>Clinical Cancer Research</i> , 2018, 24, 73-83.	3.2	113
27	How small is TOO small? New liver constraint is needed— Proton therapy of hepatocellular carcinoma patients with small normal liver. <i>PLoS ONE</i> , 2018, 13, e0203854.	1.1	8
28	Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx271.	0.4	3
29	Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4018-4018.	0.8	65
30	Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers. <i>Molecular Carcinogenesis</i> , 2017, 56, 425-435.	1.3	21
31	HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. <i>Hepatology International</i> , 2017, 11, 199-208.	1.9	13
32	Genome-wide association analysis identifies a <i>GLUL</i> haplotype for familial hepatitis B virus-related hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3966-3976.	2.0	23
33	<i>GALNT14</i> genotype-guided, sorafenib in combination with transarterial chemoembolization in hepatocellular carcinoma: An interim report of a prospective randomized controlled trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15657-e15657.	0.8	0
34	Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2016, 64, 720-731.	3.6	13
35	Percutaneous radiofrequency ablation of tumor feeding artery before target tumor ablation may reduce local tumor progression in hepatocellular carcinoma. <i>Biomedical Journal</i> , 2016, 39, 400-406.	1.4	9
36	Percutaneous radiofrequency ablation for hepatocellular carcinoma: Early termination versus standard termination of ablation procedure. <i>Advances in Digestive Medicine</i> , 2016, 3, 167-173.	0.1	0

#	ARTICLE	IF	CITATIONS
37	The Effectiveness of Multiple Electrode Radiofrequency Ablation in Patients with Hepatocellular Carcinoma with Lesions More than 3 cm in Size and Barcelona Clinic Liver Cancer Stage A to B2. <i>Liver Cancer</i> , 2016, 5, 8-20.	4.2	55
38	Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. <i>Hepatology</i> , 2015, 61, 1934-1944.	3.6	46
39	Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. <i>Liver Cancer</i> , 2015, 4, 228-240.	4.2	41
40	Insufficient Ablative Margin Determined by Early Computed Tomography May Predict the Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation. <i>Liver Cancer</i> , 2015, 4, 26-38.	4.2	77
41	Radiofrequency ablation assisted by real-time virtual sonography for hepatocellular carcinoma inconspicuous under sonography and high-risk locations. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 413-419.	0.8	6
42	Differences in Liver Fibrosis Between Patients With Chronic Hepatitis B and C. <i>Journal of Ultrasound in Medicine</i> , 2015, 34, 813-821.	0.8	23
43	Blockade of TNF- α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion. <i>Oncimmunology</i> , 2015, 4, e1040215.	2.1	40
44	Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e95870.	1.1	64
45	Combining radiofrequency ablation and ethanol injection may achieve comparable long-term outcomes in larger hepatocellular carcinoma (3.1-4 cm) and in high-risk locations. <i>Kaohsiung Journal of Medical Sciences</i> , 2014, 30, 396-401.	0.8	10
46	Local Ablation for Hepatocellular Carcinoma in Taiwan. <i>Liver Cancer</i> , 2013, 2, 73-83.	4.2	79
47	Local Ablation for Hepatocellular Carcinoma in Taiwan: Different Points between Japan, Asia and West. <i>Oncology</i> , 2010, 78, 102-106.	0.9	5
48	Recent advances in radiofrequency ablation in the treatment of hepatocellular carcinoma and metastatic liver cancers. <i>Chang Gung Medical Journal</i> , 2009, 32, 22-32.	0.7	18
49	Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2007, 46, 45-52.	1.8	306
50	Radiofrequency Ablation for Hepatocellular Carcinoma: A Prospective Comparison of Four Radiofrequency Devices. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 1118-1125.	0.2	35
51	A Sustained Virological Response to Interferon or Interferon/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan. <i>Antiviral Therapy</i> , 2006, 11, 985-994.	0.6	162
52	Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma \leq 4 cm. <i>Gastroenterology</i> , 2004, 127, 1714-1723.	0.6	600
53	Power Rolloff During Interactive Radiofrequency Ablation Can Enhance Necrosis When Treating Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2003, 180, 151-157.	1.0	25
54	Percutaneous local ablation therapy in small hepatocellular carcinoma. <i>Chang Gung Medical Journal</i> , 2003, 26, 308-14.	0.7	10

#	ARTICLE	IF	CITATIONS
55	Cytologic Changes in Small Hepatocellular Carcinomas After Radiofrequency Ablation. <i>Acta Cytologica</i> , 2002, 46, 490-494.	0.7	10
56	Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. <i>Hepatology</i> , 1999, 29, 971-975.	3.6	456
57	Etiology of sporadic acute viral hepatitis in Taiwan: The role of hepatitis C virus, hepatitis E virus and GB virus-C/hepatitis G virus in an endemic area of hepatitis A and B. , 1999, 58, 154-159.		29
58	Non-surgical treatment of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, S319-28.	1.4	125
59	Sonographic detection of hepatic portal venous gas associated with suppurative cholangitis. <i>Journal of Clinical Ultrasound</i> , 1993, 21, 331-334.	0.4	33
60	Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis. <i>Liver</i> , 1993, 13, 46-50.	0.1	34